Products Ilofotase alfa + Placebo
Ilofotase alfa + Placebo Phase 2 Completed ⚡ Active Dec 19, 2023 → Dec 3, 2025
About Ilofotase alfa + Placebo Ilofotase alfa + Placebo is a phase 2 stage product being developed by AM-Pharma for Open Heart Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT06168799. Target conditions include Open Heart Surgery.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT06168799 Phase 2 Completed Dec 19, 2023 Dec 3, 2025 Open Heart Surgery
Product Company Stage Hype Score Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved Pirtobrutinib + Placebo Eli Lilly Phase 1/2 Anti-(integrin beta-3) human monoclonal antibody Rallybio Phase 2 SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 Micafungin Astellas Pharma Approved SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Placebo + Lusutrombopag Shionogi Phase 2 Lusutrombopag Shionogi Phase 2 Avatrombopag + Avatrombopag + Placebo Eisai Phase 2 E5501 Eisai Phase 1 avatrombopag Eisai Phase 1 E5501 + Drug: E5501 Eisai Phase 1 E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food Eisai Phase 1 Eltrombopag + Avatrombopag + Standard of care Eisai Phase 3 Placebo + Avatrombopag tablets Eisai Phase 2 avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count) Eisai Phase 3 avatrombopag + Placebo Eisai Phase 2 Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin Eisai Phase 2
Other Products from AM-Pharma